Releases
ALEC
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest Alector (ALEC) stock and general news. This information may help you make smarter investment decisions.
About ALEC
Alector, Inc. is a clinical-stage biopharmaceutical company focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a cause of multiple pathologies that are drivers of degenerative brain disorders. The Company is developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. The Company's platform leverages large scale human genetic datasets, advanced tools in bioinformatics and imaging, and insights into neurodegeneration and immunology to identify immune system. Its platform focuses on target selection, biomarker selection and patient selection. Its product portfolio includes AL001, AL101, Al002 and AL003. Its AL001 targets frontotemporal dementia carrying a progranulin (FTD-GRN).